| Recruiting | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative B NCT06324240 | Emory University | Phase 1 |
| Not Yet Recruiting | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer NCT04529044 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Brea NCT06640881 | Amsterdam UMC, location VUmc | Phase 2 |
| Recruiting | Study on Recurrent Breast Cancer and Repeated Radiation Therapy NCT06704659 | Turku University Hospital | N/A |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic NCT04418219 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemo NCT04052555 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cance NCT03939897 | National Cancer Institute (NCI) | Phase 1 |
| Completed | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer NCT03554044 | University of California, San Francisco | Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Suspended | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer NCT03737695 | Mayo Clinic | — |
| Active Not Recruiting | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Ca NCT03941730 | Mayo Clinic | Phase 2 |
| Completed | Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer NCT04022772 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectabl NCT03971409 | Laura Huppert, MD, BA | Phase 2 |
| Completed | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences NCT03955640 | Thomas Jefferson University | Phase 1 |
| Withdrawn | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Ca NCT03644589 | University of Washington | Phase 2 |
| Completed | Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Communi NCT04297384 | Roswell Park Cancer Institute | N/A |
| Completed | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors NCT03725436 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positi NCT03281902 | Mayo Clinic | — |
| Recruiting | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk NCT03418961 | SWOG Cancer Research Network | Phase 3 |
| Completed | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients W NCT03364348 | George W. Sledge Jr. | Phase 1 |
| Recruiting | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Can NCT03213041 | Northwestern University | Phase 2 |
| Unknown | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hor NCT03044730 | Northwestern University | Phase 2 |
| Completed | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surg NCT02898207 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent O NCT02996825 | City of Hope Medical Center | Phase 1 |
| Completed | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or B NCT02595905 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis NCT02774681 | Northwestern University | Phase 2 |
| Terminated | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery NCT02658812 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer NCT02824575 | Montefiore Medical Center | Phase 1 |
| Withdrawn | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent NCT02627430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negat NCT02672475 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer NCT02536794 | Northwestern University | Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer NCT02157051 | University of Washington | Phase 1 |
| Active Not Recruiting | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estro NCT02311933 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic NCT02219789 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Completed | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Brea NCT06217874 | Mayo Clinic | — |
| Completed | Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Tha NCT01816035 | University of Washington | Phase 1 |
| Active Not Recruiting | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Can NCT02115282 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receivi NCT01922921 | University of Washington | Phase 1 / Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer NCT01908101 | University of Washington | Phase 2 |
| Completed | Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer NCT02415387 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01964924 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III NCT01776008 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Pa NCT01622868 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Br NCT02370264 | University of Southern California | N/A |
| Completed | Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer NCT01624441 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Pri NCT01606241 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer NCT01463072 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer NCT01575522 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relaps NCT01434303 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Br NCT01697293 | Prescient Therapeutics, Ltd. | Phase 1 / Phase 2 |
| Completed | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer NCT01349959 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT01351909 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal NCT01344031 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive NCT01327781 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer NCT01277757 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer NCT01275677 | National Cancer Institute (NCI) | Phase 3 |
| Completed | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Brea NCT01263145 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metasta NCT01281150 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer NCT01281163 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Remo NCT01276496 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01251874 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cance NCT01149356 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Canc NCT02149173 | University of Washington | N/A |
| Completed | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer NCT01145430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer NCT00998738 | Mayo Clinic | Phase 3 |
| Terminated | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Su NCT01071564 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy NCT00892736 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer NCT00699491 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or NCT00785291 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breas NCT00601900 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated NCT00684983 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU NCT00520975 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That NCT00450879 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cance NCT00390455 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT00376688 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer NCT00100750 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Re NCT00118157 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating NCT00066690 | ETOP IBCSG Partners Foundation | Phase 3 |
| Completed | Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer NCT00054132 | National Cancer Institute (NCI) | Phase 2 |